natgillin/translations-raw huggingface dataset:
The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea.
Simptomi mogu uključivati hladan znoj, umor, glavobolju, ubrzan rad srca, napadaje gladi, razdražljivost, nervozu i mučninu.
The symptoms may include one or more of the following: swelling, pain or rash around blood or lymph vessels, high level of a specific type of white blood cells (marked eosinophilia), worsening problems with breathing, nasal congestion, heart problems, pain, numbness, tingling in the arm and legs.
Simptomi mogu uključivati jedan ili više od navedenog: oticanje, bol ili osip oko krvnih ili limfnih žila, visoku razinu određene vrste bijelih krvnih stanica (značajna eozinofilija), pogoršanje problema s disanjem, začepljenje nosa, probleme sa srcem, bol, utrnulost, trnce u rukama i nogama.
The symptoms of angina are caused by the heart not receiving enough oxygenated blood.
Simptome angine uzrokuje srce koje ne prima dovoljno oksigenirane krvi.
The symptoms of fentanyl overdose are expected to be an extension of its pharmacological actions e.g. lethargy, coma and severe respiratory depression.
Simptomi predoziranja fentanilom proširenje su njegovog farmakološkog djelovanja, poput letargije, kome i teške respiratorne depresije.
The symptoms of heart failure are caused by the heart not pumping enough blood around the body.
Simptomi zatajenja srca uzrokovani su kada srce ne opskrbljuje tijelo dovoljnom količinom krvi.
The symptoms of hypoglycaemia usually occur suddenly.
Simptomi hipoglikemije obično se javljaju naglo, a mogu uključivati: hladan znoj, hladnu blijedu kožu, umor,
The symptoms of intracranial hypertension can include visual changes, headache, nausea and/or vomiting.
Simptomi intrakranijske hipertenzije mogu uključivati poremećaje vida, glavobolju, mučninu i/ili povraćanje.
The symptoms of pandemic flu are similar to those of an ordinary flu but may be more severe.
Simptomi pandemijske gripe slični su onima obične gripe, no mogu biti snažniji.
The symptoms of pandemic flu are similar to those of an ordinary flu but may be more severe.
Simptomi pandemijske influence slični su onima obične influence, no mogu biti snažniji.
The symptoms of PML may be similar to an MS relapse (e.g. weakness or visual changes).
Simptomi PML-a mogu nalikovati relapsu multiple skleroze (npr. slabost ili smetnje vida).
The symptoms of PML may be similar to an MS relapse.
Simptomi PML-a mogu biti slični onima kod relapsa MS-a.
The symptoms of serum sickness can be one or more of the following symptoms: joint pain with or without swelling or stiffness, rash, fever, swollen lymph nodes, muscle pain.
Simptomi serumske bolesti mogu uključivati jedan ili više od navedenog: bolovi u zglobovima sa ili bez oticanja ili ukočenosti, osip, vrućica, otečeni limfni čvorovi, bolovi u mišićima.
The symptoms of this condition include:
Simptomi ovog stanja uključuju:
The symptoms related to this HSR worsen with continued therapy and can be life- threatening.
Simptomi povezani s tom reakcijom preosjetljivosti pogoršavaju se s nastavkom terapije i mogu ugroziti život.
The symptoms you might experience are described in section 2 of this leaflet (please read section 2 “What you need to know before you are given Lucentis”).
Simptomi koje biste mogli osjetiti opisani su u dijelu 2 ove Upute (pročitajte dio 2 „Što morate znati prije nego počnete primjenjivati Lucentis“).
The syringe and needle should NEVER be re-used.
Štrcaljku i iglu ne smijete NIKADA ponovno koristiti.
The syringe and needle should NEVER be reused.
Ne smijete NIKADA ponovno koristiti štrcaljku i iglu.
The syringe and needle should NEVER be reused.
Štrcaljka i igla NIKADA se ne smiju ponovno upotrijebiti.
The syringe and needles should NEVER be re-used.
Štrcaljku i igle ne smijete NIKADA ponovno koristiti.
The syringe and safety needle used to administer the injection are provided with the medicinal product.
Štrcaljka i sigurnosna igla koje se koriste za primjenu injekcije isporučuju se s lijekom.
The syringe and the vial are for single use only.
Injekcija i bočica predviđene su samo za jednokratnu upotrebu.
The syringe and the vial are for single use only.
Štrcaljka i bočica namijenjene su samo za jednokratnu primjenu.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 3 days (but not above 25°C).
Štrcaljku možete izvaditi iz hladnjaka i ostaviti je na sobnoj temperaturi (ne višoj od 25°C), ali samo jednom i ne dulje od 3 dana.
The syringe can be removed from the refrigerator and left at room temperature for a single period of maximum 7 days (but not above 25°C).
Štrcaljku smijete izvaditi iz hladnjaka i ostaviti na sobnoj temperaturi (ne višoj od 25°C) jednokratno do najviše 7 dana.
the syringe cap is not detached from the Luer lock.
se zatvarač štrcaljke nije odvojio od Luer zatvarača.
The syringe contains graduation marks corresponding to 135 micrograms (mcg), 90 mcg and 45 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju 135 mikrograma (µg), 90 µg i 45 µg.
The syringe contains graduation marks corresponding to 180 micrograms (mcg), 135 mcg and 90 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju 180 mikrograma (µg), 135 µg i 90 µg.
The syringe contains graduation marks corresponding to 90 micrograms (mcg), 65 mcg, 45 mcg, 30 mcg, 20 mcg and 10 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju 90 mikrograma (µg), 65 µg, 45 µg, 30 µg, 20 µg i 10 µg.
The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 °C-25 °C. If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared.
Štrcaljku napunjenu rekonstituiranom suspenzijom treba ostaviti do 30 minuta prije primjene tako da dosegne temperaturu od oko 20 °C do 25 °C. Ako je proteklo više od 30 minuta, suspenziju treba primjereno baciti i pripremiti novu dozu.
The syringe filled with reconstituted suspension should be allowed up to 30 minutes prior to administration to reach a temperature of approximately 20 ºC-25 ºC. If the elapsed time is longer than 30 minutes, the suspension should be discarded appropriately and a new dose prepared.
Štrcaljku napunjenu rekonstituiranom suspenzijom treba ostaviti do 30 minuta prije primjene tako da dosegne temperaturu od oko 20 °C do 25 °C. Ako je proteklo više od 30 minuta, suspenziju treba primjereno baciti i pripremiti novu dozu.
The syringe fits onto the bottle and has a 2 ml scale.
Štrcaljka je oblikovana da se prilagođava bočici i ima mjernu skalu od 2 ml.
The syringe fits onto the bottle and has a 2 ml scale.
Štrcaljka je oblikovana da se prilagođava bočici i ima mjernu skalu s oznakama 2 ml.
The syringe fits onto the bottle and has a 2 ml scale.
Štrcaljka pristaje na bočicu i ima označenu sklau od 2 ml.
The syringe fits onto the bottle and has a kg- body weight scale which corresponds to the maintenance dose.
Štrcaljka se podešava na bočicu i ima skalu kg-tjelesna masa koja odgovara dozi održavanja.
The syringe fits onto the bottle and has a kg-body weight scale (from 1 kg to 10 kg) which corresponds to the maintenance dose (i.e.
Brizgalica odgovara otvoru na boci, a naznačena graduacija (od 1 do 10 kg) odgovara dozi održavanja.
The syringe fits onto the bottle and has a kg-body weight scale (from 1 kg to 10 kg) which corresponds to the maintenance dose.
Brizgalica odgovara otvoru na boci, a naznačena graduacija (od 1 do 10 kg) odgovara dozi održavanja.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e.
Brizgalica odgovara otvoru na boci, a naznačena graduacija odgovara dozi održavanja (tj.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e.
Šprica je oblikovana tako da se prilagođava boci i ima mjernu skalu s oznakama tjelesne mase u kilogramima, koji odgovaraju dozi održavanja (tj.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e.
Štrcaljka pristaje na kapaljku bočice i ima ljestvicu mjernih oznaka za tjelesnu težinu u kg, koje odgovaraju dozi održavanja (tj.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e.
Štrcaljka se namjesti na bocu i sadrži skalu kg-tjelesne težine koji odgovara dozi održavanja (tj.
The syringe fits onto the bottle and has a kg-body weight scale.
Štrcaljka pristaje na bočicu i ima označene mjere za kg tjelesne mase.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the dose of 0.05 mg meloxicam/kg bodyweight.
Štrcaljka pristaje na kapaljku bočice i ima ljestvicu mjernih oznaka za tjelesnu težinu u kg, koje odgovaraju dozi od 0,05 meloksikama/kg tjelesne mase.
The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to the maintenance dose.
Štrcaljka pristaje na kapaljku bočice i ima ljestvicu mjernih oznaka za tjelesnu težinu u kg, koje odgovaraju dozi održavanja..
The syringe has a scale on the syringe barrel.
Štrcaljka ima označenu skalu na trupu.
The syringe has a white tamper-evident cap.
Štrcaljka ima bijeli zaštitni zatvarač s evidencijom otvaranja.
The syringe has an integrated adapter and has a kg/body weight graduation.
Štrcaljka ima integrirani adapter te graduaciju za kg/tjelesnoj masi.
The syringe inside the pen is a 1 mL pre-filled syringe made of glass (Type I) with a bromobutyl rubber stopper and thermoplastic and polypropylene rigid needle shield, containing 0.5 mL of solution.
Štrcaljka unutar brizgalice je napunjena štrcaljka volumena od 1 ml od stakla (tip I) s brombutilnim gumenim čepom i termoplastičnim i polipropilenskim čvrstim štitnikom igle, koja sadrži 0,5 ml otopine.
The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger.
Štrcaljka u brizgalici napravljena je od prozirnog stakla (tipa I) s iglom od nehrđajućeg čelika od 27 G, gumenim poklopcem za iglu i plastičnim klipom.
The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger.
Štrcaljka u brizgalici napravljena je od prozirnog stakla tipa I s iglom od nehrđajućeg čelika od 27G, gumenim poklopcem za iglu i plastičnim klipom.
The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).
Štrcaljka koja se nalazi unutar brizgalice je od stakla tipa I s čepom klipa (bromobutilna guma) i iglom sa zaštitom za iglu (termoplastični elastomer).
The syringe inside the pen is made from type 1 glass with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).
Štrcaljka unutar brizgalice je izrađena od stakla tipa I, s čepom klipa (bromobutilna guma) i iglom sa zaštitom (termoplastični elastomer).
The syringe is a disposable, pre-filled delivery device.
Štrcaljka je napunjena naprava za jednokratnu primjenu lijeka.
The syringe is equipped with a light green polypropylene plunger rod.
Štrcaljka je opremljena svjetlozelenim polipropilenskim potisnikom klipa.
The syringe is for ONE-TIME USE ONLY.
Štrcaljka je namijenjena SAMO ZA JEDNOKRATNU UPORABU.
The syringe is labeled with graduations corresponding to doses of 135 mcg, 90 mcg and 45 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju dozama od 135 mikrograma, 90 mikrograma i 45 mikrograma.
The syringe is labeled with graduations corresponding to doses of 180 mcg, 135 mcg and 90 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju dozama od 180 mikrograma, 135 mikrograma i 90 mikrograma.
The syringe is labeled with graduations corresponding to doses of 90 mcg, 65 mcg, 45 mcg, 30 mcg, 20 mcg and 10 mcg.
Na štrcaljki se nalaze oznake koje odgovaraju dozama od 90 mikrograma, 65 mikrograma, 45 mikrograma, 30 mikrograma, 20 mikrograma i 10 mikrograma.
The syringe is made from type 1 glass with a plunger stopper (bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer).
Štrcaljka je izrađena od stakla tipa I, s čepom klipa (bromobutilna guma) i iglom sa zaštitom za iglu (termoplastični elastomer).
the syringe is not damaged. the solution looks clear, colourless to pale yellow and does not contain any particles.
štrcaljka nije oštećena. otopina izgleda bistro, bezbojna je do blijedožuta i ne sadrži nikakve čestice.
The syringe is now ready for injection.
Štrcaljka je sada spremna za injekciju.
The syringe may then be removed and the contents of the infusion bag mixed gently by inverting the bag several times.
Štrcaljka se zatim smije ukloniti i sadržaj infuzijske vrećice nježno promiješati preokretanjem vrećice nekoliko puta.
The syringe must be protected from light, and discarded if not used within the 14 -day period.
Štrcaljku se mora zaštiti od svjetlosti i zbrinuti ako se ne iskoristi unutar 14 dana.
The syringe should not be shaken.
Brizgalicu ili štrcaljku se ne smije tresti.
The syringe should not be shaken.
Napunjena štrcaljka ne smije se tresti.
The syringe should not be shaken.
Štrcaljke se ne smiju tresti.
The syringe should then be removed from the filter and a new needle placed on the suspension-filled syringe.
Štrcaljku zatim treba odvojiti od filtra i na štrcaljku sa suspenzijom staviti novu iglu.
The syringe, needle, vial and vial adapter MUST NEVER be reused.
Uporabljenu štrcaljku, iglu, bočicu i nastavak NE SMIJETE NIKADA ponovno koristiti.
the syringe/pen is cracked or broken
je štrcaljka/brizgalica napuknuta ili slomljena
the syringe/pen is cracked or broken.
štrcaljka/brizgalica napuknuta ili slomljena.
The syringes are packed into cardboard boxes as follows; 10 syringes.
Štrcaljke su pakirane u kartonske kutije kako slijedi; 10 štrcaljki.
The syringes are pre-filled with the exact dose you need.
Štrcaljka je napunjena s točnom dozom lijeka koju trebate.
The syringes are provided either with or without a blister wrapping.
Štrcaljke se isporučuju u blisteru ili bez blistera.
The syringes are provided with an automatic needle guard.
Štrcaljke se isporučuju s automatskim sigurnosnim sustavom za iglu.
The syringes are sealed in a blister.
Štrcaljke su zatvorene u blisteru.
The syringes are type I glass-fitted with stainless-steel needles.
Štrcaljke su od stakla tipa I opremljene iglom od nehrđajućeg čelika.
The syringes are type I glass.
Štrcaljke su napravljene od stakla tipa I.
The syringes fit onto the bottle and have a kg-bodyweight scale which corresponds to the maintenance dose (i.e.
Štrcaljke se podešavaju na bočicu i imaju skalu kg-tjelesna masa koja odgovara dozi održavanja (tj.
The syringes in this titration pack are marked accordingly with the appropriate doses (0.25; 0.5; 0.75 or 1.0 ml).
Štrcaljke u tom titracijskom pakiranju označene su odgovarajućim dozama (0,25, 0,5, 0,75 ili 1,0 ml).
The syringes should be of small enough volume that the prescribed dose can be withdrawn from the vial with reasonable accuracy.
Štrcaljka treba biti dovoljno malog volumena kako bi se propisana doza mogla povući iz bočice s razumnom preciznošću.
The syrup contains aspartame (E951), a source of phenylalanine, which may be harmful for people with phenylketonuria.
Sirup sadrži aspartam (E951), izvor fenilalanina, koji može biti štetan u osoba s fenilketonurijom.
The system does not check your blood glucose; therefore you need to check your blood glucose at least 4 times a day according to the method and frequency recommended by your physician;
Sustav ne provjerava razinu glukoze u krvi; stoga razinu glukoze u krvi morate provjeravati najmanje 4 puta na dan u skladu s načinom i učestalošću koju Vam je preporučio liječnik;
The system is fully activated when a ‘click’ is heard.
Sustav je u potpunosti aktiviran kad se začuje 'klik'.
The systemic availability and half-life of nateglinide in diabetic patients with mild, moderate (creatinine clearance 31–50 ml/min) and severe (creatinine clearance 15–30 ml/min) renal impairment (not undergoing dialysis) did not differ to a clinically significant degree from those in healthy subjects.
Sistemska raspoloživost i poluvrijeme života nateglinida u bolesnika sa šećernom bolešću s blagim, umjerenim (klirens kreatinina 31-50 ml/min) i teškim (klirens kreatinina 15-30 ml/min) oštećenjem bubrega (koji se ne podvrgavaju dijalizi) nije se razlikovao u klinički značajnoj mjeri od onih u zdravih ispitanika.
The systemic bioavailability of robenacoxib tablets in dogs was 62% with food and 84% without food.
Sistemska bioraspoloživost tableta robenakoksiba u pasa iznosila je 62 % s hranom i 84 % bez hrane.
The systemic bioavailability of robenacoxib tablets was 49% without food.
Sistemska raspoloživost tableta robenakoksiba bez hrane iznosila je 49 %.
The systemic bioavailability of the veterinary medicinal product is approximately 40%.
Sustavna bioraspoloživost veterinarsko- medicinskog proizvoda je otprilike 40%.
The systemic clearance is 18 - 64 mL/min/kg.
Sistemski klirens je 18 – 64 mL/min/kg.
The systemic clearance of emtricitabine averaged 307 ml/min (4.03 ml/min/kg).
Sistemski klirens emtricitabina u prosjeku je iznosio 307 ml/min (4,03 ml/min/kg).
The systemic emtricitabine exposure (mean ± standard deviation) increased from 11.8±2.9 µg·h/ml in subjects with normal renal function to 19.9±1.1, 25.0±5.7 and 34.0±2.1 µg·h/ml, in patients with mild, moderate and severe renal impairment, respectively.
Sistemska izloženost emtricitabinu (srednja vrijednost ± standardna devijacija) povećala se s 11,8±2,9 µg·h/ml u ispitanika s normalnom funkcijom bubrega na 19,9±1,1 µg·h/ml u pacijenata s blagim oštećenjem funkcije bubrega, 25,0±5,7 µg·h/ml u pacijenata s umjerenim oštećenjem funkcije bubrega i 34,0±2,1 µg·h/ml u pacijenata s teškim oštećenjem funkcije bubrega.
The systemic exposure (AUC) to etravirine was decreased by about 50% when INTELENCE was administered under fasting conditions, as compared to administration following a meal.
Sistemska izloženost (AUC) etravirinu bila je smanjena za oko 50% kada je INTELENCE primjenjivan natašte u usporedbi s primjenom nakon obroka.
The systemic exposure at the lowest dose was below or comparable to that observed in humans (based on AUC0-) at the recommended human dose.
Sistemska izloženost pri najnižoj dozi bila je niža ili se mogla usporediti s onom zapaženom kod ljudi (na osnovu AUC0-) pri preporučenoj dozi za ljude.
The systemic exposure at this dose represents 2 – 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 – 2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients.
Sistemska izloženost pri tim dozama je 2 - 3 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan kod bolesnika s presađenim bubregom i 1,3 - 2 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem.
The systemic exposure at this dose represents 2 – 3 times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3 – 2 times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients.
Sistemska izloženost pri tim dozama je 2 - 3 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan kod bolesnika s presađenim bubregom i 1,3 - 2 puta veće od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem.
The systemic exposure at this dose represents 2 – 3 times the clinical exposure at the recommended clinical dose of 2 g/day.
Sistemska izloženost pri tim dozama je 2 - 3 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan.
The systemic exposure at this dose represents 2-3°times the clinical exposure at the recommended clinical dose of 2 g/day in renal transplant patients and 1.3-2°times the clinical exposure at the recommended clinical dose of 3 g/day in cardiac transplant patients.
Sistemska izloženost pri tim dozama je 2 - 3 puta veća od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan kod bolesnika s presađenim bubregom i 1,3 – 2 puta veće od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem.
The systemic exposure based on Cmax and AUC for free aflibercept were approximately 200- and 700-fold higher, respectively, when compared to corresponding values observed in humans after an intravitreal dose of 2 mg.
Sistemska izloženost na temelju Cmax slobodnog aflibercepta bila je približno 200 puta veća, a na temelju AUC 700 puta veća u usporedbi s vrijednostima tih parametara opaženih u ljudi nakon intravitrealne doze od 2 mg.
The systemic exposure data demonstrated that the extent of absorption of imiquimod following topical application to the MC lesional skin of the paediatric patients aged 6-12 years was low and comparable to that observed in healthy adults and adults with actinic keratosis or superficial basal cell carcinoma.
Podaci o sustavnoj izloženosti pokazuju da je stupanj apsorpcije imikvimoda nakon lokalne primjene kroz kožu u području lezije MC u djece u dobi od 6 do 12 godina bio nizak i uporediv s apsorpcijom u zdrave djece i odraslih s aktiničnom keratozom ili površinskim bazeocelularnim karcinomom kože.
The systemic exposure of N-desmethylated metabolite was 25% of the parent compound, while the oxydechlorinated metabolite was 19% of the parent compound.
Sistemska izloženost N- desmetiliranog metabolita bila je 25% ishodišnog lijeka, dok je oksidekloriniran metabolit bio 19% ishodišnog lijeka.
The systemic use of VEGF inhibitors, substances similar to those contained in Eylea, is potentially related to the risk of blood clots blocking blood vessels (arterial thromboembolic events) which may lead to heart attack or stroke.
Postoji mogućnost da je sistemska primjena inhibitora VEGF-a, tvari koje su slične onima koje sadrži lijek Eylea, povezana s rizikom od začepljenja krvnih žila krvnim ugrušcima (arterijski tromboembolijski događaji) što može dovesti do srčanog udara ili moždanog udara.
The systemic use of VEGF inhibitors, substances similar to those contained in Eylea, is potentially related to the risk of blood clots blocking blood vessels (arterial thromboembolic events) which may lead to heart attack or stroke.
Postoji mogućnost da su sistemski inhibitori VEGF-a, tvari koje su slične onima koje sadrži Eylea, povezani s rizikom od začepljenja krvnih žila krvnim ugrušcima (arterijski tromboembolijski događaji) što može dovesti do srčanog udara ili moždanog udara.
The t1/2 of bosutinib increased in hepatic impaired patients as compared to the healthy subjects.
U bolesnika s oštećenjem funkcije jetre t1/2 bosutiniba porastao je u odnosu na zdrave ispitanike.
The table 5 shows bleeding events broken down to major and any bleeding in the pivotal study testing the prevention of thromboembolic stroke and SEE in patients with atrial fibrillation.
Tablica 5 pokazuje incidenciju krvarenja kategoriziranih na velika ili bilo kakva krvarenja u ključnoj studiji prevencije tromboembolijskog moždanog udara i SE-a u bolesnika s fibrilacijom atrija.
The table 5 shows the number (%) of patients experiencing the adverse reaction bleeding during the treatment period in the VTE prevention in the two pivotal clinical trials, according to dose.
Tablica 5 pokazuje broj (%) bolesnika koji su imali krvarenje tijekom razdoblja liječenja u prevenciji VTE-a u dva ključna klinička ispitivanja, prema dozi.
The table 6 shows bleeding events broken down to major and any bleeding in the pivotal study testing the prevention of thromboembolic stroke and SEE in patients with atrial fibrillation.
Tablica 6 pokazuje događaje krvarenja kategoriziranih na velika ili bilo kakva krvarenja u ključnoj studiji prevencije tromboembolijskog moždanog udara i SE-a u bolesnika s fibrilacijom atrija.
The table also includes side effects which occurred in less than 10% but were significantly associated with the treatment.
Tablica također uključuje nuspojave koje su se dogodile u manje od 10 % bolesnika, ali su bile značajno povezane s liječenjem.